Dieulafoy's lesions are a cause of GI bleeding.
The results of hemoclip application as the first treatment of choice for Dieulafoy's lesions have not yet been reported.
In this study, researchers from Japan examined the short- and long-term outcomes of hemoclip application for Dieulafoy's lesions.
The research team conducted the study over a 7-year period, which began in 1995.
|The rate of recurrent bleeding was 9%.|
During the course of the study, hemoclip application was used as the first-choice hemostatic treatment for Dieulafoy's lesions.
The team evaluated clinical data, endoscopic findings, and treatment outcome. Long-term outcome was also investigated.
The researchers diagnosed a Dieulafoy's lesion in 34 patients (27 men, 7 women) after a mean of 1.2 endoscopies. Of these patients, 79% had active bleeding.
The team found that initial hemostasis was attained by hemoclip placement in 94%.
Furthermore, the rate of recurrent bleeding was 9% and no patient required additional treatment.
They found that the 30-day mortality rate was 3%. For the remaining 33 patients, median follow-up was 53.8 months.
A further lesion developed in 1 patient during follow-up. However, this was in a different location to the index lesion.
Dr Yasuharu Yamaguchi's team concluded, "Endoscopic hemoclip application for Dieulafoy's lesions was effective and safe with short- and long-term benefits".